Abstract
Primary effusion lymphoma (PEL) is a large B-cell neoplasm with an unfavorable prognosis and limited therapeutic options. In this study, cancer testis antigens (CTA) were investigated as potential immunotherapeutic targets in patients with PEL. Baseline expression of a panel of 11 CTA was highly heterogeneous among five PEL cell lines. In particular, the investigated CTA were not expressed in BC-2 and BC-3 cells, while BC-1, HBL-6, and BCBL-1 cells tested positive for 6, 8, and 9 CTA, respectively. The DNA hypomethylating agent 5-aza-2'-deoxycytdine (5-AZA-CdR) invariably induced or up-regulated the expression of all investigated CTA in all cell lines analyzed. The de novo expression of CTA was still detectable at mRNA and protein level at least 2 months after the end of 5-AZA-CdR treatment. These findings, and the concomitant up-regulation of HLA-class I antigens and ICAM-1 by 5-AZA-CdR, support its clinical use to set-up innovative chemo-immunotherapeutic approaches in PEL.
References
Feb 1, 1989·Hybridoma·M TemponiS Ferrone
Sep 1, 1995·The Journal of Experimental Medicine·B Van den EyndeT Boon
Nov 3, 1995·International Journal of Cancer. Journal International Du Cancer·F BrasseurY Humblet
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·C De SmetT Boon
Oct 1, 1996·Genome Research·C A HeidP M Williams
Oct 27, 1997·Leukemia·H M KantarjianM Talpaz
Feb 7, 1998·The Journal of Experimental Medicine·E JägerA Knuth
Jun 17, 1998·International Journal of Cancer. Journal International Du Cancer·B LethéT Boon
Jan 30, 1999·Journal of Immunotherapy·S CoralM Maio
Apr 24, 1999·Leukemia·J FelgnerR Parwaresch
Oct 16, 1999·International Journal of Cancer. Journal International Du Cancer·A SerranoT Boon
Mar 4, 2000·International Journal of Cancer. Journal International Du Cancer·A O GüreY T Chen
Jun 8, 2000·International Journal of Cancer. Journal International Du Cancer·A I RikerF M Marincola
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·E JägerA Knuth
Oct 18, 2000·Advances in Cancer Research·G Gaidano, A Carbone
Mar 21, 2002·Cancer Investigation·Alexei F KirkinJesper Zeuthen
Sep 28, 2002·Blood·Michael DaskalakisMichael Lübbert
Jan 28, 2003·Journal of Cellular Physiology·Albert J W ZendmanGoos N P Van Muijen
May 21, 2003·Blood·Luca SigalottiMichele Maio
Oct 7, 2003·Oncogene·Michele MaioLuca Sigalotti
Nov 8, 2003·Blood·Jean-Pierre J IssaHagop M Kantarjian
Citations
Nov 10, 2012·Cancer Immunology, Immunotherapy : CII·Sandra CoralMichele Maio
Mar 1, 2010·Genes & Cancer·Stefano AmatoriMirco Fanelli
Jan 5, 2011·PloS One·Rouzbeh TaghizadehCaterina A M La Porta
May 15, 2013·PloS One·Li-Xin WangLi Yu
Sep 1, 2009·The American Journal of Pathology·Andrew G Muntean, Jay L Hess
Apr 27, 2007·Journal of Cellular Physiology·Luca SigalottiMichele Maio
Jul 28, 2011·Journal of Cellular Physiology·Luana CalabròMichele Maio
Feb 4, 2010·Journal of Cellular Physiology·Elisabetta FrattaMichele Maio
Oct 8, 2005·Seminars in Oncology·Luca SigalottiMichele Maio
Oct 8, 2005·Seminars in Oncology·Valter GatteiMichele Maio
Mar 8, 2011·Molecular Oncology·Elisabetta FrattaMichele Maio
Oct 9, 2015·PloS One·Agnes S KlarChristoph Renner
Jan 22, 2008·Journal of Cellular Physiology·Luca SigalottiMichele Maio
Aug 23, 2012·British Journal of Cancer·S CoralM Maio
May 6, 2016·Cancer Informatics·Mariama El BaroudiEnrico Capobianco
Jan 1, 2014·Journal of Biomarkers·Ramyar MolaniaBahar Mahjoubi
Sep 5, 2013·Molecular Medicine Reports·Jihao ZhouLi Yu
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ester FonsattiMichele Maio